Nuvectis Pharma, Inc. is a biopharmaceutical company. The Company is focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. It seeks to develop drug candidates in the precision medicine space, and its processes for selection and clinical development of drug candidates is based on scientific insights into cancer-promoting factors, as well as on its understanding of the clinical landscape and regulatory requirements. The Company is primarily engaged in developing two drug candidates, NXP800 and NXP900. Its lead product candidate, NXP800 is a clinical-stage, oral small-molecule inhibitor of the Heat Shock Factor 1 (HSF1) pathway for the treatment of platinum resistant, adenine-thymine (AT)-rich interaction domain (ARID1a)-mutated ovarian carcinoma. NXP900 is a targeted-therapy, small-molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases for the treatment of SRC-associated solid tumors.
